Early Pregnancy Biomarkers in Pre-Eclampsia: A Systematic Review and Meta-Analysis
Tóm tắt
Pre-eclampsia (PE) complicates 2%–8% of all pregnancies and is an important cause of perinatal morbidity and mortality worldwide. In order to reduce these complications and to develop possible treatment modalities, it is important to identify women at risk of developing PE. The use of biomarkers in early pregnancy would allow appropriate stratification into high and low risk pregnancies for the purpose of defining surveillance in pregnancy and to administer interventions. We used formal methods for a systematic review and meta-analyses to assess the accuracy of all biomarkers that have been evaluated so far during the first and early second trimester of pregnancy to predict PE. We found low predictive values using individual biomarkers which included a disintegrin and metalloprotease 12 (ADAM-12), inhibin-A, pregnancy associated plasma protein A (PAPP-A), placental growth factor (PlGF) and placental protein 13 (PP-13). The pooled sensitivity of all single biomarkers was 0.40 (95% CI 0.39–0.41) at a false positive rate of 10%. The area under the Summary of Receiver Operating Characteristics Curve (SROC) was 0.786 (SE 0.02). When a combination model was used, the predictive value improved to an area under the SROC of 0.893 (SE 0.03). In conclusion, although there are multiple potential biomarkers for PE their efficacy has been inconsistent and comparisons are difficult because of heterogeneity between different studies. Therefore, there is an urgent need for high quality, large-scale multicentre research in biomarkers for PE so that the best predictive marker(s) can be identified in order to improve the management of women destined to develop PE.
Từ khóa
Tài liệu tham khảo
Ghulmiyyah, 2012, Maternal mortality from preeclampsia/eclampsia, Semin. Perinatol., 36, 56, 10.1053/j.semperi.2011.09.011
Duley, 2003, Pre-eclampsia and the hypertensive disorders of pregnancy, Br. Med. Bull., 67, 161, 10.1093/bmb/ldg005
Roberts, 2013, If we know so much about preeclampsia, why haven’t we cured the disease?, J. Reprod. Immunol., 99, 1, 10.1016/j.jri.2013.05.003
North, R.A., McCowan, L.M., Dekker, G.A., Poston, L., Chan, E.H., Stewart, A.W., Black, M.A., Taylor, R.S., Walker, J.J., and Baker, P.N. (2011). Clinical risk prediction for pre-eclampsia in nulliparous women: Development of model in international prospective cohort. BMJ, 342.
Shennan, 2012, Are most maternal deaths from pre-eclampsia avoidable?, Lancet, 379, 1686, 10.1016/S0140-6736(11)60785-X
Grill, S., Rusterholz, C., Zanetti-Dallenbach, R., Tercanli, S., Holzgreve, W., Hahn, S., and Lapaire, O. (2009). Potential markers of preeclampsia—A review. Reprod. Biol. Endocrinol., 7.
Zhong, 2010, First-trimester assessment of placenta function and the prediction of preeclampsia and intrauterine growth restriction, Prenat. Diagn., 30, 293, 10.1002/pd.2475
Tranquilli, 2014, The classification, diagnosis and management of the hypertensive disorders of pregnancy: A revised statement from the isshp, Pregnancy Hypertens., 4, 97, 10.1016/j.preghy.2014.02.001
Anderson, U.D., Olsson, M.G., Rutardottir, S., Centlow, M., Kristensen, K.H., Isberg, P.E., Thilaganathan, B., Akerstrom, B., and Hansson, S.R. (2011). Fetal hemoglobin and α1-microglobulin as first- and early second-trimester predictive biomarkers for preeclampsia. Am. J. Obstet. Gynecol., 204.
Akolekar, 2008, Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsia, Ultrasound Obstet. Gynecol., 32, 732, 10.1002/uog.6244
Akolekar, 2013, Competing risks model in early screening for preeclampsia by biophysical and biochemical markers, Fetal Diagn. Ther., 33, 8, 10.1159/000341264
Audibert, F., Boucoiran, I., An, N., Aleksandrov, N., Delvin, E., Bujold, E., and Rey, E. (2010). Screening for preeclampsia using first-trimester serum markers and uterine artery doppler in nulliparous women. Am. J. Obstet. Gynecol., 203.
Bills, 2009, Failure to up-regulate VEGF165b in maternal plasma is a first trimester predictive marker for pre-eclampsia, Clin. Sci., 116, 265, 10.1042/CS20080270
Bosio, 2001, Plasma P-selectin is elevated in the first trimester in women who subsequently develop pre-eclampsia, BJOG, 108, 709
Boucoiran, 2013, Risks for preeclampsia and small for gestational age: Predictive values of placental growth factor, soluble fms-like tyrosine kinase-1, and inhibin a in singleton and multiple-gestation pregnancies, Am. J. Perinatol., 30, 607
Boucoiran, 2013, Repeated measures of placental growth factor, placental protein 13, and a disintegrin and metalloprotease 12 at first and second trimesters for preeclampsia screening, Am. J. Perinatol., 30, 681, 10.1055/s-0032-1331025
Brameld, 2008, First trimester predictors of adverse pregnancy outcomes, Aust. N. Z. J. Obstet. Gynaecol., 48, 529, 10.1111/j.1479-828X.2008.00912.x
Chafetz, I., Kuhnreich, I., Sammar, M., Tal, Y., Gibor, Y., Meiri, H., Cuckle, H., and Wolf, M. (2007). First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction. Am. J. Obstet. Gynecol., 197.
Cohen, 2014, Predictive value of combined serum biomarkers for adverse pregnancy outcomes, Eur. J. Obstet. Gynecol. Reprod. Biol., 181, 89, 10.1016/j.ejogrb.2014.07.018
Cowans, 2011, PP13 as a marker of pre-eclampsia: A two platform comparison study, Placenta, 32, S37, 10.1016/j.placenta.2010.08.014
Deurloo, 2013, ADAM12s and PP13 as first trimester screening markers for adverse pregnancy outcome, Clin. Chem. Lab. Med., 51, 1279, 10.1515/cclm-2012-0566
Dugoff, 2004, First-trimester maternal serum papp-a and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: A population-based screening study (the faster trial), Am. J. Obstet. Gynecol., 191, 1446, 10.1016/j.ajog.2004.06.052
Giguere, 2015, Screening for pre-eclampsia early in pregnancy: Performance of a multivariable model combining clinical characteristics and biochemical markers, BJOG, 122, 402, 10.1111/1471-0528.13050
Goetzinger, 2013, Efficiency of first-trimester uterine artery doppler, A-disintegrin and metalloprotease 12, pregnancy-associated plasma protein A, and maternal characteristics in the prediction of preeclampsia, J. Ultrasound Med., 32, 1593, 10.7863/ultra.32.9.1593
Gonen, 2008, Placental protein 13 as an early marker for pre-eclampsia: A prospective longitudinal study, BJOG, 115, 1465, 10.1111/j.1471-0528.2008.01902.x
Ghosh, 2013, Is serum placental growth factor more effective as a biomarker in predicting early onset preeclampsia in early second trimester than in first trimester of pregnancy?, Arch. Gynecol. Obstet., 287, 865, 10.1007/s00404-012-2662-2
Hedley, 2010, Free leptin index and PAPP-A: A first trimester maternal serum screening test for pre-eclampsia, Prenat. Diagn., 30, 103, 10.1002/pd.2337
Kang, 2008, Down syndrome biochemical markers and screening for preeclampsia at first and second trimester: Correlation with the week of onset and the severity, Prenat. Diagn., 28, 704, 10.1002/pd.1997
Kenny, 2014, Early pregnancy prediction of preeclampsia in nulliparous women, combining clinical risk and biomarkers: The screening for pregnancy endpoints (scope) international cohort study, Hypertension, 64, 644, 10.1161/HYPERTENSIONAHA.114.03578
Khalil, 2010, First-trimester markers for the prediction of pre-eclampsia in women with a-priori high risk, Ultrasound Obstet. Gynecol., 35, 671, 10.1002/uog.7559
Kuc, 2013, Maternal characteristics, mean arterial pressure and serum markers in early prediction of preeclampsia, PLoS ONE, 8, e63546, 10.1371/journal.pone.0063546
Kusanovic, 2009, A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsia, J. Matern. Fetal Neonatal Med., 22, 1021, 10.3109/14767050902994754
Myatt, 2012, First-trimester prediction of preeclampsia in nulliparous women at low risk, Obstet. Gynecol., 119, 1234, 10.1097/AOG.0b013e3182571669
Myers, 2013, Angiogenic factors combined with clinical risk factors to predict preterm pre-eclampsia in nulliparous women: A predictive test accuracy study, BJOG, 120, 1215, 10.1111/1471-0528.12195
Nicolaides, 2007, Some thoughts on the true value of ultrasound, Ultrasound Obstet. Gynecol., 30, 671, 10.1002/uog.5156
Odibo, 2011, First-trimester placental protein 13, PAPP-A, uterine artery doppler and maternal characteristics in the prediction of pre-eclampsia, Placenta, 32, 598, 10.1016/j.placenta.2011.05.006
Park, H.J., Kim, S.H., Jung, Y.W., Shim, S.S., Kim, J.Y., Cho, Y.K., Farina, A., Zanello, M., Lee, K.J., and Cha, D.H. (2014). Screening models using multiple markers for early detection of late-onset preeclampsia in low-risk pregnancy. BMC Pregnancy Childbirth, 14.
Poon, 2009, First-trimester maternal serum pregnancy-associated plasma protein-a and pre-eclampsia, Ultrasound Obstet. Gynecol., 33, 23, 10.1002/uog.6280
Poon, 2009, First-trimester maternal serum matrix metalloproteinase-9 (MMP-9) and adverse pregnancy outcome, Prenat. Diagn., 29, 553, 10.1002/pd.2234
Roes, E.M., Gaytant, M.A., Thomas, C.M., Raijmakers, M.T., Zusterzeel, P.L., Peters, W.H., and Steegers, E.A. (2004). First trimester inhibin-A concentrations and later development of preeclampsia. Acta Obstet. Gynecol. Scand., 83.
Schneuer, 2012, First trimester screening of maternal placental protein 13 for predicting preeclampsia and small for gestational age: In-house study and systematic review, Placenta, 33, 735, 10.1016/j.placenta.2012.05.012
Spencer, 2007, First-trimester maternal serum PP-13, PAPP-A and second-trimester uterine artery doppler pulsatility index as markers of pre-eclampsia, Ultrasound Obstet. Gynecol., 29, 128, 10.1002/uog.3876
Spencer, 2008, Maternal serum inhibin-A and activin-a levels in the first trimester of pregnancies developing pre-eclampsia, Ultrasound Obstet. Gynecol., 32, 622, 10.1002/uog.6212
Tidwell, 2001, Low maternal serum levels of placenta growth factor as an antecedent of clinical preeclampsia, Am. J. Obstet. Gynecol., 184, 1267, 10.1067/mob.2001.113129
Thilaganathan, 2010, Early-pregnancy multiple serum markers and second-trimester uterine artery doppler in predicting preeclampsia, Obstet. Gynecol., 115, 1233, 10.1097/AOG.0b013e3181dd5137
Xu, 2014, The predictive value of the first-trimester maternal serum chemerin level for pre-eclampsia, Peptides, 62, 150, 10.1016/j.peptides.2014.10.002
Youssef, 2011, Uterine artery doppler and biochemical markers (PAPP-A, PIGF, sFlt-1, P-selectin, NGAL) at 11 + 0 to 13 + 6 weeks in the prediction of late (>34 weeks) pre-eclampsia, Prenat. Diagn., 31, 1141, 10.1002/pd.2848
Yu, 2011, Inhibin A, activin A, placental growth factor and uterine artery doppler pulsatility index in the prediction of pre-eclampsia, Ultrasound Obstet. Gynecol., 37, 528, 10.1002/uog.8800
Zong, 2012, Changes in the level of serum high-temperature requirement A1 (HtrA1) during pregnancy and its relationship to preeclampsia, Hypertens Pregnancy, 31, 389, 10.3109/10641955.2012.667472
Yang, 2005, A disintegrin and metalloprotease 21 (ADAM21) is associated with neurogenesis and axonal growth in developing and adult rodent CNS, J. Comp. Neurol., 490, 163, 10.1002/cne.20659
Cho, 1997, Genomic organization of the mouse fertilin β gene that encodes an ADAM family protein active in sperm-egg fusion, Dev. Genet., 20, 320, 10.1002/(SICI)1520-6408(1997)20:4<320::AID-DVG3>3.0.CO;2-9
White, 2003, ADAMS: Modulators of cell–cell and cell–matrix interactions, Curr. Opin. Cell Biol., 15, 598, 10.1016/j.ceb.2003.08.001
Zhabin, 2003, Review: Immunomodulatory activity of pregnancy-associated plasma protein-a, J. Clin. Lab. Immunol., 52, 41
Ghosh, 2012, Serum PLGF as a potential biomarker for predicting the onset of preeclampsia, Arch. Gynecol. Obstet., 285, 417, 10.1007/s00404-011-1960-4
Baviera, 2008, Endoglin, PLGF and sFlt-1 as markers for predicting pre-eclampsia, Acta Obstet. Gynecol. Scand., 87, 837, 10.1080/00016340802253759
Zhu, 2015, Pulsatility index in combination with biomarkers or mean arterial pressure for the prediction of pre-eclampsia: Systematic literature review and meta-analysis, Ann. Med., 47, 414, 10.3109/07853890.2015.1059483
Allen, 2014, Abnormal blood biomarkers in early pregnancy are associated with preeclampsia: A meta-analysis, Eur. J. Obstet. Gynecol. Reprod. Biol., 182, 194, 10.1016/j.ejogrb.2014.09.027
Kuc, 2011, Evaluation of 7 serum biomarkers and uterine artery Doppler ultrasound for first-trimester prediction of preeclampsia: A systematic review, Obstet. Gynecol. Surv., 66, 225, 10.1097/OGX.0b013e3182227027
Navaratnam, K., Alfirevic, Z., Baker, P., Gluud, C., Gruttner, B., Kublickiene, K., Zeeman, G., and Kenny, L. (2013). A multi-centre phase IIa clinical study of predictive testing for preeclampsia: Improved pregnancy outcomes via early detection (IMPROVED). BMC Pregnancy Childbirth, 13.
Villar, 2004, World health organization systematic review of screening tests for preeclampsia, Obstet. Gynecol., 104, 1367, 10.1097/01.AOG.0000147599.47713.5d
Wilson, J., and Jungner, G. (1968). Principles and Practice of Screening, World Health Organization.
Pepe, 2008, Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: Standards for study design, J. Natl. Cancer Inst., 100, 1432, 10.1093/jnci/djn326
Dancey, 2010, Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents, Clin. Cancer Res., 16, 1745, 10.1158/1078-0432.CCR-09-2167
Whiting, P., Rutjes, A., Reitsma, J.B., Bossuyt, P.M., and Kleijnen, J. (2003). The development of QUADAS: A tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med. Res. Methodol., 3.
Whiting, 2011, QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies, Ann. Intern. Med., 155, 529, 10.7326/0003-4819-155-8-201110180-00009
Whiting, P., Harbord, R., and Kleijnen, J. (2005). No role for quality scores in systematic reviews of diagnostic accuracy studies. BMC Med. Res. Methodol., 5.
Zamora, 2006, Meta-disc: A software for meta-analysis of test accuracy data, BMC Med. Res. Methodol., 6, 31, 10.1186/1471-2288-6-31